Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer combo drug tested in tiny safety study

NCT ID NCT06894771

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested the safety of an experimental drug called MK-4700, given alone or with the approved immunotherapy Keytruda, in 5 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to find a safe dose and see how the body handles the drug. Because it's a Phase 1 trial with very few participants, it cannot tell us if the drug works against cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MK-4700 (an experimental biologic) and pembrolizumab (Keytruda)
What this could lead to
If successful, this could point toward a safe dose of MK-4700 for further testing in larger cancer trials.
What could go wrong
This is a very early, small study (only 5 people) focused on safety, not effectiveness. The drug may not work or could have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

5 people

The number who actually took part.

Started

Apr 2025

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Has histologically or cytologically confirmed advanced/metastatic solid tumor by pathology report who have experienced disease progression on or after prior anti-cancer treatments, or been intolerant to, or refused all treatment known to confer clinical benefit * Has head and neck squamous cell carcinoma (HNSCC), melanoma (cutaneous), non-small cell lung cancer (NSCLC), cervical cancer, triple negative breast cancer (TNBC), urothelial carcinoma (UC), or renal cell carcinoma (RCC; clear cell, papillary) * If human immunodeficiency virus (HIV) infected, must have well controlled HIV on antiretroviral therapy (ART) * Has normal cardiac function Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * If HIV-infected with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has known additional malignancy that is progressing or has required active treatment within the past 2 years * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy * Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids * Has current pneumonitis/interstitial lung disease * Has active infection requiring systemic therapy * Has known history of Hepatitis B (defined as Hepatitis B surface antigen reactive) or known active Hepatitis C virus infection * Has had an allogeneic tissue/solid organ transplant in the last 5 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer cervical cancer head and neck squamous cell carcinoma melanoma neoplasm non-small cell lung carcinoma renal cell carcinoma Squamous Cell Carcinoma of Head and Neck transitional cell carcinoma triple-negative breast carcinoma urothelial carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malignant neoplasm

Contacts and locations

Locations

  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0102)

    Québec, Quebec, G1J 1Z4, Canada

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0301)

    Hackensack, New Jersey, 07601, United States

  • NEXT Oncology ( Site 0300)

    San Antonio, Texas, 78229, United States

  • Princess Margaret Cancer Center ( Site 0101)

    Toronto, Ontario, M5G 2M9, Canada

  • Rabin Medical Center ( Site 0202)

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus ( Site 0201)

    Haifa, 3109601, Israel

  • Sheba Medical Center ( Site 0200)

    Ramat Gan, 5265601, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.